1717 LSV empowers scientists and investors to transform early stage radiopharmaceutical projects into attractive assets for licensing partners in industry.
 

By introducing early stage investors to promising new projects, 1717 LSV seeks to enable novel radiopharmaceutical therapies to traverse the early stages of manufacturing and clinical development.